Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction: Insights From the 2-Year Follow-Up of the BIOSCIENCE Trial

JACC Cardiovasc Interv. 2016 May 9;9(9):981-3. doi: 10.1016/j.jcin.2016.02.044.
No abstract available

Publication types

  • Letter

MeSH terms

  • Absorbable Implants
  • Clinical Trials as Topic
  • Drug-Eluting Stents*
  • Everolimus / administration & dosage
  • Follow-Up Studies
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Myocardial Infarction
  • Percutaneous Coronary Intervention*
  • Polymers
  • Sirolimus / administration & dosage
  • Treatment Outcome

Substances

  • Immunosuppressive Agents
  • Polymers
  • Everolimus
  • Sirolimus